PR Newswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 21:00:00时区推断·⟳ 抓取 21:00:50·⚡ 决策 07-30 21:10:14 +9m24s·88.8 天前
BioMarin宣布将于8月6日举行二季度财报电话会
本次新闻稿仅通知二季度财报电话会和 webcast 的时间、拨入方式及投资者关系入口，未披露营收、利润、指引、临床进展或商业化新增信息。
📄 原文PR Newswire Biotechnology↗ 原文
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alex…
不做 BioMarin Pharmaceutical（BMRN.US）
例行财报电话会预告，无业绩数据、指引变化或其它新增方向内容，不形成可回测交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次新闻稿仅通知二季度财报电话会和 webcast 的时间、拨入方式及投资者关系入口，未披露营收、利润、指引、临床进展或商业化新增信息。
- 事件属于例行投资者日程公告，不形成对BioMarin Pharmaceutical（BMRN.US）短周期收入、利润或估值预期的明确新增方向。
主要风险
- 后续真正财报和业务更新可能产生交易事件，但当前通知本身没有可交易增量。
原文全文
展开原文 · 1,642 字
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss second quarter 2026 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 3551298
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 3551298
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts: |
|
Investors |
Media |
Traci McCarty |
Marni Kottle |
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(650) 374-2803 |
SOURCE BioMarin Pharmaceutical Inc.
Dial-in Number
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 3551298
U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 3551298
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts: |
|
Investors |
Media |
Traci McCarty |
Marni Kottle |
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(650) 374-2803 |
SOURCE BioMarin Pharmaceutical Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。